HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $221.00 price target on the stock. HC Wainwright's target price suggests a potential upside of 18.98% from the company's current price.

A number of other analysts have also commented on KRYS. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Citigroup upped their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Stifel Nicolaus lifted their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. William Blair raised Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Finally, Evercore ISI raised their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $202.29.

Krystal Biotech Trading Up 0.7 %

NASDAQ:KRYS traded up $1.34 during mid-day trading on Tuesday, hitting $185.74. 250,040 shares of the company's stock were exchanged, compared to its average volume of 321,838. The firm has a market capitalization of $5.34 billion, a P/E ratio of 104.94 and a beta of 0.80. The company has a 50 day simple moving average of $181.31 and a 200-day simple moving average of $184.78. Krystal Biotech has a fifty-two week low of $103.83 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period in the prior year, the firm posted ($0.67) EPS. The company's quarterly revenue was up 879.9% on a year-over-year basis. As a group, analysts expect that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently added to or reduced their stakes in KRYS. State Street Corp lifted its stake in Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company's stock worth $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock worth $107,714,000 after buying an additional 11,411 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Krystal Biotech by 1.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company's stock valued at $106,593,000 after acquiring an additional 7,537 shares during the last quarter. Hood River Capital Management LLC boosted its holdings in Krystal Biotech by 5.1% during the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company's stock valued at $95,694,000 after acquiring an additional 25,507 shares during the period. Finally, Franklin Resources Inc. grew its position in Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after acquiring an additional 62,178 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).